Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) >= 1%: Open-label, phase 3 KEYNOTE-042 study

G Lopes, YL Wu, I Kudaba, D Kowalski, BC Cho, G Castro, V Srimuninnimit, I Bondarenko, K Kubota, GM Lubiniecki, J Zhang, DA Kush, T Mok

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Article numberLBA4
JournalJournal of Clinical Oncology
Issue number18, Suppl.
Publication statusPublished - 20 Jun 2018
Externally publishedYes
Event2018 American Society of Clinical Oncology (ASCO) Annual Meeting - Chicago, United States
Duration: 1 Jun 20185 Jun 2018

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Cite this